Cost‐effectiveness of sitagliptin‐based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy

Abstract

Compared with adding rosiglitazone or a SU to MF, adding sitagliptin to MF is projected to be either cost saving or cost-effective for patients with type 2 diabetes who are not at HbA1C goal on MF.